Florian Rosar

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

Fadi Khreish, Niklas Ebert, Martin Ries et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 207 citations

Urology, Genitourinary Cancer, Medicine +7

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Fadi Khreish, Zaidoon Ghazal, Robert J. Marlowe et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 83 citations · Full text

Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy

Florian Rosar, Fabian Hau, Mark Bartholomä et al. · Theranostics · 2021 · 80 citations · Full text

Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

Florian Rosar, Jonas Krause, Mark Bartholomä et al. · Pharmaceutics · 2021 · 57 citations · Full text

New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide

Florian Rosar, Sebastian Dewes, Martin Ries et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 55 citations

Urology, Tumoral Psma Expression, Medicine +10